What is the first-line medical therapy for prolactinoma?

What is the first-line medical therapy for prolactinoma?

• A. Estrogen therapy
• B. Dopamine agonists (cabergoline, bromocriptine)
• C. Thyroid hormone replacement
• D. Dopamine antagonists

Answer: (B)

Prolactin-secreting pituitary tumors cause high prolactin, which shuts down GnRH and leads to menstrual irregularities, infertility, and galactorrhea. Dopamine normally keeps prolactin in check, so using a dopamine agonist directly reduces prolactin release and often shrinks the tumor. This makes dopamine agonists the best first-line therapy. Cabergoline (and bromocriptine) activate dopamine D2 receptors on lactotroph cells, suppressing prolactin release and lowering levels toward normal. Cabergoline is typically preferred because it is more effective, better tolerated, and taken less frequently (often once or twice weekly) than bromocriptine, though bromocriptine remains an option if cabergoline isn’t available or in certain pregnancy-related scenarios. Estrogen therapy would not treat the underlying tumor and can worsen symptoms related to hyperprolactinemia. Thyroid hormone replacement addresses hypothyroidism, which can raise prolactin indirectly but doesn’t treat a prolactinoma specifically. Dopamine antagonists increase prolactin by blocking dopamine’s inhibitory effect and are counterproductive for this condition.

Prolactin-secreting pituitary tumors cause high prolactin, which shuts down GnRH and leads to menstrual irregularities, infertility, and galactorrhea. Dopamine normally keeps prolactin in check, so using a dopamine agonist directly reduces prolactin release and often shrinks the tumor. This makes dopamine agonists the best first-line therapy.

Cabergoline (and bromocriptine) activate dopamine D2 receptors on lactotroph cells, suppressing prolactin release and lowering levels toward normal. Cabergoline is typically preferred because it is more effective, better tolerated, and taken less frequently (often once or twice weekly) than bromocriptine, though bromocriptine remains an option if cabergoline isn’t available or in certain pregnancy-related scenarios.

Estrogen therapy would not treat the underlying tumor and can worsen symptoms related to hyperprolactinemia. Thyroid hormone replacement addresses hypothyroidism, which can raise prolactin indirectly but doesn’t treat a prolactinoma specifically. Dopamine antagonists increase prolactin by blocking dopamine’s inhibitory effect and are counterproductive for this condition.